Paragon ii clinical trial
WebThe Paragon study is a basket protocol that includes a series of phase 2 trials investigating the activity of anastrozole in patients with estrogen or progesterone receptor-positive recurrent gynecological cancers. We report the results of treatment in patients with platinum-resistant or -refractory recurrent epithelial ovarian cancer. WebPARAGON-HF is the largest clinical trial in HFpEF patients performed to date. The double-blind, randomised, active-controlled parallel-group, phase three, two-arm trial compared Entresto’s long-term effectiveness and safety to valsartan in 4,822 HFpEF patients.
Paragon ii clinical trial
Did you know?
WebApr 10, 2024 · PARAGON: a phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. ... the ALIENOR/ENGOT-ov7 randomized clinical trial. JAMA Oncol, 6 (2024), pp. 1923-1930, 10.1001/jamaoncol.2024.4574.
WebNov 18, 2024 · The PARAGON-HF (ClinicalTrials.gov number, NCT01920711) investigated HF subjects class II to IV HF, ejection fraction of 45% or higher, elevated level of … WebFeb 11, 2024 · Universal Trial Number (UTN) Trial acronym PARAGON-II Linked study record This trial builds on the PARAGON study (ACTRN12610000796088) that treated …
WebFeb 16, 2009 · PARAGON II - A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal … WebNov 13, 2024 · PARAGON II - Victorian Cancer Trials Link Monday to Friday from 9am-5pm. Home > Trial Details PARAGON II : The activity and tolerability of Aromatase …
WebNational Center for Biotechnology Information
WebMain conclusions of PARAGON so far ... How to join a clinical trial. Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified. Print page. Email this page. Questions to ask your doctor about clinical trials. reach by designWebNov 13, 2024 · PARAGON II - Victorian Cancer Trials Link Monday to Friday from 9am-5pm. Home > Trial Details PARAGON II : The activity and tolerability of Aromatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic gynaecological neoplasms (PARAGON-II) Female Only Status … reach by unfoundWebNov 18, 2024 · The PARAGON-HF (ClinicalTrials.gov number, NCT01920711) investigated HF subjects class II to IV HF, ejection fraction of 45% or higher, elevated level of … how to spot clean cashmereWebMar 17, 2014 · Detailed Description: This is a prospective, interventional, non-randomized, worldwide, multi-center trial, with each site following a common protocol. A maximum of 1300 subjects will be implanted at a maximum of 40 sites in the US, Europe and Canada. The trial will include male and female patients of legal age to provide informed consent in ... reach by doeWebThe trial had a primary end-point of tumour resectability (R0 resection). Secondary end-points included safety, pathologic tumour response and overall survival. Results: 40 … reach business definitionWebJul 6, 2024 · The clinical syndrome of heart failure with preserved ejection fraction (HFpEF) is characterized broadly by signs and symptoms of heart failure and in the absence of a reduced left ventricular ejection fraction. 1 Precise definition and diagnostic clinical criteria for HFpEF remain controversial but, for the purposes of inclusion in … reach by rentcafeWebJul 29, 2024 · PARAGON-HF is the largest clinical trial in heart failure with preserved ejection fraction (HFpEF) conducted to date[7]. The Phase III randomized, double-blind, parallel group, active-controlled, 2-arm, event-driven trial compared the long-term efficacy and safety of sacubitril/valsartan versus valsartan in 4,822 patients with HFpEF[7]. reach by gloria estefan lyrics